To identify which pediatric cancers might benefit from developing CCT2 as a molecular target, we analyzed the KidsFirst/CBTTC cohort (21 datasets) and the TARGET Pan-Cancer cohort (12 datasets) by cancer type. Here, CCT2 is linked to cancer.